4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$23.96 USD
-0.94 (-3.78%)
Updated May 29, 2024 04:00 PM ET
After-Market: $23.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FDMT 23.96 -0.94(-3.78%)
Will FDMT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
Other News for FDMT
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Dynavax (DVAX) and Natera (NTRA)
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)
Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Oculis Holding (OCS)
4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections